Cullinan Oncology transitions CSO Patrick Baeuerle to advisor; stockholders elect directors

Cullinan Therapeutics, Inc.

Dr. Baeuerle transitions from Chief Scientific Officer to Co-Founder & Chief Scientific Advisor, effective June 8, 2023.
Consulting agreement: $40,556 monthly, max $480,000/year, with bonus opportunity (40% in 2023, 25% thereafter).
Stockholders elected Nadim Ahmed (28,651,746 votes for) and Stephen Webster (21,598,415 for) as Class III directors.
Ratification of KPMG LLP as independent auditor for FY2023 approved with 34,563,271 votes for.
Term of consulting agreement runs through Dec 31, 2024, with annual auto-renewal; either party may terminate on 180 days notice.

item 5.02 item 5.07

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Patrick Baeuerle

Co-Founder, Chief Scientific Advisor

CGEM · Cullinan Therapeutics, Inc.

Effective: 2023-06-08
Filed: June 14, 2023, 7:59 PM ET

Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Patrick Baeuerle changed role as Co-Founder, Chief Scientific Advisor at Cullinan Therapeutics, Inc..

Action: transitioned
Role: Co-Founder, Chief Scientific Advisor

Exact text from the filing

Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Cullinan Therapeutics, Inc. shareholders approved Election of two Class III directors to serve for three-year terms at the 2023-06-08 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Proposal One — Election of Directors The Company’s stockholders elected two Class III directors to the Company’s Board of Directors for three-year terms or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Nadim Ahmed 28,651,746 346,553 5,838,068 Stephen Webster 21,598,415 7,399,884 5,838,068

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Cullinan Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-08

Exact text from the filing

Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 34,563,271 272,925 171 0

View on SEC.gov

Browse all shareholder votes →

Cullinan Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-027958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.